Insomnia is difficulty falling or staying asleep, or non-restorative sleep, that causes daytime impairment. For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment — medications are used as adjuncts. Zolpidem (Ambien) is the most prescribed sleep aid, while trazodone, hydroxyzine, and low-dose quetiapine are commonly used off-label due to their non-habit-forming profiles.
Insomnia: Medications, Treatment & Drug Guide
Insomnia is the most common sleep disorder, affecting roughly 10–30% of adults chronically and an even higher percentage transiently. It is characterized by dissatisfaction with sleep quantity or quality — difficulty initiating sleep, difficulty maintaining sleep, or early morning awakening — accompanied by daytime consequences such as fatigue, cognitive impairment, mood disturbance, or functional impairment.
Insomnia is not simply a symptom to suppress with medication. In its chronic form, it is a disorder driven by a cycle of learned arousal, hypervigilance around sleep, and counterproductive coping behaviors. Understanding this distinction is essential to understanding why the evidence base strongly favors behavioral interventions over long-term medication use.
Overview: Acute vs Chronic Insomnia & Treatment Approach
Acute Insomnia
Acute insomnia is short-term, typically triggered by identifiable stressors — a life event, grief, a new environment, shift changes, illness, or stimulant medications. Most episodes resolve spontaneously once the precipitating factor passes. Short-term use of sleep aids may be appropriate for acute insomnia when sleep deprivation is significantly impairing function, but even in acute cases, establishing good sleep hygiene practices reduces the risk of transition to chronic insomnia.
Chronic Insomnia
Chronic insomnia — defined as three or more nights per week of poor sleep for at least three months — often develops a self-perpetuating character. Initial triggers may resolve, but the hyperarousal, anxiety around sleep, and compensatory behaviors (excessive time in bed, irregular sleep schedules, daytime napping) keep the cycle alive. This is precisely why CBT-I, which directly targets these perpetuating factors, outperforms medication in long-term outcomes.
The Role of CBT-I
Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia by the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society — ahead of any medication. It produces durable improvements without dependency risk.
CBT-I typically includes: sleep restriction therapy (temporarily limiting time in bed to consolidate sleep), stimulus control (reserving bed only for sleep and sex), cognitive restructuring (addressing dysfunctional beliefs about sleep), relaxation techniques, and sleep hygiene education. It is available through licensed therapists, psychologists, and increasingly through validated digital programs when in-person access is limited.
Sleep Hygiene Basics
Sleep hygiene practices support — but do not replace — CBT-I or medication when indicated. Key elements include: maintaining a consistent wake time (even after a poor sleep night), limiting caffeine after early afternoon, keeping the bedroom cool and dark, avoiding screens in the hour before bed (bright light suppresses melatonin), and avoiding alcohol as a sleep aid (see interactions below).
Medications Used for Insomnia
About the Medications
Zolpidem (Ambien) is the most commonly prescribed sleep medication in the United States. It is a non-benzodiazepine GABA-A receptor agonist ("Z-drug") that produces sedation by enhancing the inhibitory effects of GABA in the brain. It is FDA-approved for short-term insomnia treatment. Despite not being a benzodiazepine structurally, zolpidem carries significant risks: tolerance, dependence, complex sleep behaviors (sleepwalking, sleep-driving — particularly in women), and rebound insomnia upon discontinuation. It is classified as a Schedule IV controlled substance.
Trazodone is an antidepressant (serotonin antagonist and reuptake inhibitor) that is one of the most widely prescribed off-label treatments for insomnia. Its sedating effects come from H1 histamine and 5-HT2 receptor antagonism at low doses — these same properties that cause drowsiness as a side effect when treating depression become the target effect for insomnia. Trazodone is not a controlled substance and does not carry the same dependency risks as Z-drugs or benzodiazepines, making it popular for longer-term management.
Hydroxyzine is a first-generation antihistamine with anxiolytic and sedative properties, used off-label for insomnia — particularly in patients with comorbid anxiety. It is not habit-forming and not a controlled substance. Tolerance to its sedating effects can develop with regular use. Anticholinergic effects (dry mouth, urinary retention, constipation) are more pronounced in older adults, who should use it with caution.
Melatonin (over-the-counter) is a hormone naturally secreted by the pineal gland in response to darkness, signaling the circadian timing of sleep. OTC melatonin supplements are most effective for circadian rhythm disruptions (jet lag, shift work, delayed sleep phase) rather than classic insomnia. Evidence for sleep-onset insomnia is modest. No full drug page is linked here as it is OTC, but it is considered low-risk for most adults at typical supplemental amounts.
Quetiapine (Seroquel) is an atypical antipsychotic prescribed off-label at very low doses for insomnia, despite being approved only for schizophrenia, bipolar disorder, and major depression. Its histamine-blocking properties produce sedation at these low doses. Off-label use for insomnia is controversial — it carries metabolic risks (weight gain, elevated blood sugar), movement side effects, and other significant adverse effects that many clinicians consider disproportionate for a non-psychiatric sleep complaint.
Mirtazapine (Remeron) is an antidepressant with potent H1 antagonism that makes it highly sedating, particularly at lower doses. It is prescribed off-label for insomnia, especially in patients with comorbid depression, poor appetite, or anxiety. Like trazodone, it is non-habit-forming, though it is associated with weight gain and increased appetite as common side effects.
Other Approved Sleep Medications
- Benzodiazepines (temazepam, triazolam) — FDA-approved for insomnia but carry significant dependency, tolerance, and rebound risks; generally not recommended for long-term use.
- Suvorexant (Belsomra) — An orexin receptor antagonist that promotes sleep by blocking the wake-promoting orexin system; a newer mechanism with a cleaner side effect profile but higher cost.
- Lemborexant (Dayvigo) — Another orexin receptor antagonist with evidence for both sleep onset and maintenance insomnia.
- Ramelteon (Rozerem) — A melatonin receptor agonist approved for sleep-onset insomnia; the only prescription sleep medication that is not a controlled substance and carries essentially no dependency risk.
- Doxepin (Silenor) — A tricyclic antidepressant approved at very low doses for sleep maintenance insomnia; works primarily via H1 antagonism at these doses.
Common Drug Interactions
- Melatonin and alcohol interaction
- Trazodone and alcohol interaction
- Alcohol and lorazepam (benzodiazepine) interaction
Alcohol is widely but mistakenly used as a sleep aid. While it does reduce sleep-onset time, alcohol disrupts sleep architecture — suppressing REM sleep in the first half of the night, then causing rebound arousal and fragmented sleep in the second half as it is metabolized. When combined with sedative sleep medications (Z-drugs, benzodiazepines, trazodone, hydroxyzine, quetiapine), alcohol can produce dangerous additive CNS depression, increasing the risk of profound sedation, respiratory depression, and accidents.
Other important interactions include: CNS depressants combined with Z-drugs or benzodiazepines (opioids, muscle relaxants, antihistamines — all increase sedation risk), CYP3A4 inhibitors that raise zolpidem levels (ketoconazole, erythromycin), and trazodone with MAO inhibitors or serotonergic drugs (serotonin syndrome risk).
Side Effects to Watch For
Z-drugs and benzodiazepines carry risks of dependence, tolerance, rebound insomnia, next-day sedation ("hangover effect"), impaired driving, and in older adults, increased fall and fracture risk. Zolpidem has a specific black box warning for complex sleep behaviors — patients have reported sleepwalking, sleep-eating, and even driving while not fully awake. Off-label sedating agents have their own profiles: quetiapine carries metabolic risk and extrapyramidal effects; hydroxyzine has anticholinergic burden; trazodone can cause orthostatic hypotension and priapism (a rare but serious side effect).
Comparison Guides
Ambien and trazodone represent two fundamentally different approaches to medication-assisted sleep. Zolpidem is FDA-approved, fast-acting, and highly effective short-term, but carries controlled substance classification and dependency risk. Trazodone is off-label, takes longer to act, has a milder efficacy profile, but is non-addictive and better tolerated for longer-term use in appropriate patients.
Frequently Asked Questions
What is the difference between acute and chronic insomnia?
Acute insomnia lasts days to a few weeks and is usually tied to an identifiable stressor. It often resolves on its own once the trigger passes. Chronic insomnia is defined as difficulty falling or staying asleep at least three nights per week for three months or more, and often persists independently even after the original cause has resolved. Chronic insomnia is driven in part by learned arousal patterns and hypervigilance around sleep, which is why CBT-I is the recommended first-line treatment.
What is CBT-I and why is it recommended over sleep medications?
CBT-I (Cognitive Behavioral Therapy for Insomnia) is a structured, evidence-based therapy that addresses the thoughts, behaviors, and habits perpetuating chronic insomnia. It typically includes sleep restriction therapy, stimulus control, relaxation techniques, and sleep hygiene education. Multiple clinical trials show CBT-I produces durable improvements that outlast medication effects — and without the dependency risks or next-day sedation associated with many sleep aids. Guidelines from major sleep medicine societies recommend CBT-I as first-line treatment for chronic insomnia.
Is trazodone a sleep medication?
Trazodone is an antidepressant that is very widely prescribed off-label for insomnia at much lower doses than used for depression. Its sedating properties come from histamine H1 and serotonin 5-HT2 receptor antagonism. Because it is non-habit-forming and does not carry the same dependency risks as benzodiazepines or Z-drugs, many clinicians favor it for chronic insomnia management. However, it is not FDA-approved for sleep and evidence for its sleep-specific efficacy is more limited than for approved agents.
Is melatonin effective for insomnia?
Melatonin, available over the counter, is most effective for circadian-related sleep problems — jet lag, shift work sleep disorder, and delayed sleep phase — rather than classic insomnia. Its efficacy for sleep-onset insomnia is modest at best in the general adult population. Melatonin is considered low-risk and may provide some benefit for certain individuals, but it is not a substitute for CBT-I in chronic insomnia. It is particularly useful for older adults, as endogenous melatonin production declines with age.
⚠ This article is for informational purposes only and does not constitute medical advice. Sleep medication decisions should be made with a qualified healthcare provider. Never combine sleep medications with alcohol. If you are experiencing a mental health crisis or have thoughts of self-harm, call or text 988.